Amyris (NASDAQ:AMRS) Trading Up 7%

Amyris, Inc. (NASDAQ:AMRSGet Rating) shares traded up 7% on Wednesday . The company traded as high as $2.90 and last traded at $2.90. 22,826 shares traded hands during trading, a decline of 100% from the average session volume of 8,861,265 shares. The stock had previously closed at $2.71.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AMRS shares. Roth Capital cut shares of Amyris from a “buy” rating to a “neutral” rating in a report on Wednesday, August 10th. JPMorgan Chase & Co. began coverage on Amyris in a report on Friday, June 24th. They set a “neutral” rating on the stock. Finally, Piper Sandler started coverage on shares of Amyris in a research report on Wednesday, May 25th. They set a “neutral” rating and a $2.50 price objective for the company.

Amyris Stock Up 11.1 %

The company has a quick ratio of 1.13, a current ratio of 1.66 and a debt-to-equity ratio of 1.26. The firm has a 50 day moving average of $2.49 and a two-hundred day moving average of $3.09. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -2.38 and a beta of 1.36.

Amyris (NASDAQ:AMRSGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $81.53 million. During the same quarter in the previous year, the business earned ($0.16) earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amyris, Inc. will post -1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Nicole Kelsey sold 94,033 shares of Amyris stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $1.80, for a total transaction of $169,259.40. Following the sale, the insider now directly owns 63,333 shares of the company’s stock, valued at $113,999.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Nicole Kelsey sold 94,033 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $1.80, for a total value of $169,259.40. Following the completion of the sale, the insider now owns 63,333 shares of the company’s stock, valued at $113,999.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John Melo sold 55,576 shares of Amyris stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $2.12, for a total value of $117,821.12. Following the completion of the transaction, the chief executive officer now directly owns 492,701 shares in the company, valued at $1,044,526.12. The disclosure for this sale can be found here. Insiders own 33.80% of the company’s stock.

Institutional Trading of Amyris

A number of institutional investors have recently bought and sold shares of the company. Gordian Capital Singapore Pte Ltd bought a new stake in Amyris in the fourth quarter valued at $26,000. Point72 Hong Kong Ltd acquired a new position in Amyris during the 2nd quarter worth approximately $29,000. Hudock Inc. bought a new position in Amyris in the first quarter worth approximately $31,000. Rafferty Asset Management LLC bought a new stake in shares of Amyris during the second quarter valued at approximately $37,000. Finally, Prospera Financial Services Inc acquired a new position in shares of Amyris during the first quarter worth approximately $39,000. Institutional investors own 43.08% of the company’s stock.

About Amyris

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Featured Articles

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.